UNSPSC 51414001: Hexadiline

This classification denotes a vasodilating agent with the molecular formula C19H33N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5T8Q3G88U, chemically known as 2-(2,2-dicyclohexylvinyl)piperidine but generally known as hexadiline, which bears US NIH Compound Identifier 219119. European Medicines Agency schedules Hexadiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08025MIG.

UNSPSC 51414001 Hexadiline is a Commodity code under which state and local governments procure advanced life support medications and other pharmaceutical products for emergency medical services, state health agencies, and cooperative purchasing consortiums. The scope of work encompasses the supply of specific branded and generic medications—such as epinephrine injections, labetalol, adenosine, and diltiazem—meeting strict expiration-date requirements, FDA compliance, and OSHA hazard communication standards. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Recent solicitations show work spanning emergency medicine supply, pharmacy benefit program optimization, and bulk generic pharmaceutical distribution to state and local facilities across multiple jurisdictions.

Activity appears concentrated in Florida and Minnesota, with additional engagement from Texas state health agencies. The City of Tampa's Purchasing Department issued an IFB (Solicitation No. 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the contract includes a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (Solicitation No. S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness beginning July 1, 2026; this procurement operates through three authorized wholesalers and serves participating state and local government facilities across Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in April 2026 seeking vendor capabilities regarding direct-to-manufacturer prescription programs, signaling potential future formal solicitations.